IMMX News and Press, Immix Biopharma Inc. From 08/18/23

Dr. Landau joins the Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Memorial Sloan Kettering Cancer Center Dr. Landau is a recognized thought leader in CAR-T cell therapy, bone marrow and solid organ transplantation and novel treatment appr...

LOS ANGELES, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that additi...

LOS ANGELES, July 25, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced that updated NXC-201 relapsed/refractory multiple myeloma clinical data has been sele...

Tumor shrinkage was observed in 3 out of 4 (75%) patients; 1 out of 4 (25%) experienced tumor control as of the July 7, 2023 clinical data cutoff date. All patients had stage IV relapsed/refractory metastatic colorectal cancer and received 8 median lines of therapy prior to IMX-110 + tislelizumab...

LOS ANGELES, July 10, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced the completion of its initial CAR-T NXC-201 engineering batch at its U.S. manufacturi...

2023-07-07 12:50:55 ET Gainers: Prestige Wealth ( PWM ) +90% . Castle Biosciences ( CSTL ) +52% . Near Intelligence ( NIR ) +44% . T2 Biosystems ( TTOO ) +37% . Greenidge Generation Holdings ( GREE ) +31% . The Real Good Food...

2023-06-27 10:07:53 ET Gainers: Black Diamond Therapeutics ( BDTX ) +91% . Cara Therapeutics ( CARA ) +27% . Pharvaris ( PHVS ) +21% . AC Immune ( ACIU ) +11% . Immix Biopharma ( IMMX ) +6% . Losers: Adicet Bio ( ACET ...

LOS ANGELES, June 26, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering cell therapies targeting oncology and other diseases, ...

Mr. Borkowski joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical and healthcare industry, including 7 years as Chief Financial Officer of Mylan N.V. Mr. Borkowski is also the former Chief Financial Officer of CareFusion, which was ultimatel...

Mr. Cooper joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical industry, including 5 years as Chief Financial Officer of BioMarin Pharmaceutical Mr. Cooper is a former independent director of Sierra Oncology, acquired by GlaxoSmithKline for ...